Scholar Rock Holding Reports Promising Results for SRK-439 in Weight Management Research

Scholar Rock Advances Weight Management Research with Promising Antimyostatin Antibody Data

Scholar Rock Holding, a late-stage biopharmaceutical company based in Cambridge, Massachusetts, announces encouraging results from preclinical studies of its investigational antimyostatin antibody, SRK-439. This antibody shows potential in enhancing lean body mass and mitigating fat mass gain when used in conjunction with metformin. The findings, set to be presented by Dr. Melissa Fulham at the upcoming ObesityWeek conference in San Antonio, Texas, highlight a significant step forward in the company’s efforts to address obesity and related metabolic disorders.

In a study utilizing a murine model of diet-induced obesity, Scholar Rock’s research team administers metformin over four weeks to mice placed on a high-fat diet. Following this period, the mice receive either SRK-439 or an IgG control antibody for an additional four weeks. The results are striking: young mice treated with SRK-439 alongside metformin demonstrate a two-fold increase in lean mass compared to the group receiving metformin alone. Specifically, lean mass increases by 31.6% from baseline in the SRK-439 group, a significant contrast to the 15.1% increase witnessed in controls (p<0.0001). In older mice, the impact is even more pronounced, with a remarkable 50-fold enhancement in lean mass compared to control subjects.

These findings reinforce Scholar Rock's hypothesis that selective myostatin inhibition may positively influence body composition among individuals grappling with obesity and related conditions, such as diabetes. Jay Backstrom, President and CEO of Scholar Rock, emphasizes the importance of these results, suggesting they pave the way for future therapeutic strategies targeting weight management and overall metabolic health. Looking ahead, Scholar Rock is poised to advance its cardiometabolic program, with topline data from the Phase 2 EMBRAZE trial anticipated in the second quarter of 2025, further underlining the potential of SRK-439 in promoting healthier weight management solutions.

In addition to the preclinical data, Scholar Rock continues to position itself as a leader in biopharmaceutical innovation. The company’s commitment to advancing treatments for underserved medical needs, particularly in the realm of metabolic disorders, reflects its strategic focus on harnessing biological mechanisms for improved patient outcomes. The upcoming presentation at ObesityWeek is expected to garner significant attention from the medical and scientific communities, aligning with Scholar Rock’s vision of addressing critical health challenges through targeted therapies.